Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences Corp. (NASDAQ: EXAS) shares hiked Wednesday. The company, a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged ...
A next-generation multitarget stool DNA test for colorectal cancer screening had higher sensitivity but lower specificity than a currently available FIT, according to the large prospective BLUE-C study.
13.03.2024 - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, 'Next-Generation ... Seite 1
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.The<a class="excerpt-read-more" href="https://whdh.com/news/a-blood-test-for-colon-cancer-performed-well-in-a-study-expanding-options-for-screening/">Read More</a>
Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included...